CAR-T therapy utilizing Oncostatin-M ligand demonstrates significant anti-tumor efficacy in osteosarcoma treatment - Top-Institutions - MDSpire

CAR-T therapy utilizing Oncostatin-M ligand demonstrates significant anti-tumor efficacy in osteosarcoma treatment

  • By

  • Daniel Feinberg

  • Vinayak Uppin

  • Saada Eid

  • Claire Fritz

  • Masahiro Hitomi

  • Akshaya Radhakrishnan

  • Kayla Klatt

  • Sung Hee Choi

  • Jay T Myers

  • Aarshvi Bhatt

  • Duncan Stearns

  • Irina Pateva

  • Zachary D C Burke

  • Alex Y Huang

  • Gary K Schwartz

  • Reshmi Parameswaran

  • March 17, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    St. Jude Children's Research Hospital
    St. Jude Children's Research Hospital

    Memphis, TN

    Key Differentiators

    • Pediatric Oncology
    • Immunotherapy
    • Cellular Therapy

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Medical Oncology
    • Immunotherapy
    • Cellular Therapy

  • #3

    National Cancer Institute (NCI), NIH
    National Cancer Institute (NCI), NIH

    Bethesda, MD

    Key Differentiators

    • Cancer Immunotherapy
    • Pediatric Oncology
    • Translational Research

  • #4

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Pediatric Oncology
    • Immunotherapy
    • Cell Therapy

Original Source(s)

CAR-T therapy utilizing Oncostatin-M ligand demonstrates significant anti-tumor efficacy in osteosarcoma treatment

  • by Daniel Feinberg, Vinayak Uppin, Saada Eid, Claire Fritz, Masahiro Hitomi, Akshaya Radhakrishnan, Kayla Klatt, Sung Hee Choi, Jay T Myers, Aarshvi Bhatt, Duncan Stearns, Irina Pateva, Zachary D C Burke, Alex Y Huang, Gary K Schwartz, Reshmi Parameswaran

  • March 17, 2026

Related Content

Development and validation of a machine learning-based risk prediction model for cancer-related fatigue in ovarian cancer patients

Interaction of CD99 and its ligands regulates immunoregulatory pathways in NK cells

Clonal Hematopoiesis does not influence manufacturing of Chimeric Antigen Receptor (CAR) T-Cells